TRAIL and Its Receptors in Oral Cancer Progression
Author Information
Author(s): Vigneswaran Nadarajah, Baucum Darryl C, Wu Jean, Lou Yahuan, Bouquot Jerry, Muller Susan, Zacharias Wolfgang
Primary Institution: The University of Texas Health Science Center at Houston
Hypothesis
The study investigates the expression levels of TRAIL and its receptors during the progression of oral cancer.
Conclusion
Loss of TRAIL expression is an early event during oral carcinogenesis and may contribute to the molecular carcinogenesis of oral squamous cell carcinoma (OSCC).
Supporting Evidence
- Normal oral epithelia expressed TRAIL, but its expression was lost in oral premalignancies and OSCC.
- Reduction in DcR2 expression was noted in OPM and OSCC compared to normal oral mucosa.
- Expression levels of DR4, DR5, and DcR1 were not significantly altered in OPM and OSCC compared to normal oral mucosa.
- High DR5 expression in primary OSCC correlated with larger tumor size.
- No significant association was found between TRAIL-R expression and OSCC histology grade or nodal status.
Takeaway
TRAIL is a protein that helps kill cancer cells, but it gets lost as oral cancer develops, which might help the cancer grow.
Methodology
The study used DNA microarray, immunoblotting, and immunohistochemical analyses to examine TRAIL and its receptor expression in various oral tissues.
Potential Biases
Potential biases may arise from the selection of tissue samples and the methods used for analysis.
Limitations
The study may not account for all factors influencing TRAIL expression and its receptors in oral cancer.
Participant Demographics
{"median_age":42,"age_range":"37–81","sex_distribution":{"male":29,"female":13}}
Statistical Information
P-Value
p ≤ 0.001
Statistical Significance
p ≤ 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website